Literature DB >> 25838093

Leukotriene E4 induces MUC5AC release from human airway epithelial NCI-H292 cells.

Hideaki Shirasaki1, Etsuko Kanaizumi2, Nobuhiko Seki2, Tetsuo Himi2.   

Abstract

BACKGROUND: Hypersecretion of mucin in the airway epithelium is an important feature of allergic airway diseases. Of the 3 cysteinyl leukotrienes (CysLTs; LTC4 LTD4 and LTE4), only LTE4 is sufficiently stable to be detectable in extracellular fluids. However, LTE4 has received little attention because it binds poorly to the CysLT1 and CysLT2 receptors; therefore, little is known about the effects of LTE4 on mucous secretion. Recently, studies have focused on the P2Y12 receptor as a potential receptor for LTE4, because this receptor is required for LTE4-mediated pulmonary inflammation. In our previous study, we confirmed the expression of P2Y12 receptor in human airway epithelial cells. To clarify the roles of LTE4 in airway epithelial cells, we investigated mucus secretion by LTE4 in vitro.
METHODS: Confluent NCI-H292 cells were stimulated with LTE4 (0.01-1 μM) for 24 h. The release and production of MUC5AC protein, a gel-forming mucin, were evaluated with an enzyme-linked immunosorbent assay.
RESULTS: Western blot analysis revealed that NCI-H292 cells expressed P2Y12 receptor protein. LTE4 significantly induced the release of MUC5AC mucin in a dose-dependent manner. Th2 cytokines such as IL-4 (10 ng/mL) and IL-13 (10 ng/mL) accelerated the LTE4-induced release of MUC5AC protein. MRS2935, a P2Y12 receptor antagonist, partially inhibited the LTE4-induced release of MUC5AC protein in the airway. In contrast, MK571, a CysLT1 receptor antagonist, did not affect the release of MUC5AC protein elicited by LTE4.
CONCLUSIONS: These results suggest that LTE4 may play some important roles in allergic mucus secretion partially via activation of P2Y12 receptor.
Copyright © 2014 Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Allergic mucous secretion; Epithelial cells; Leukotriene E(4); MUC5AC mucin; P2Y(12) antagonist

Mesh:

Substances:

Year:  2015        PMID: 25838093     DOI: 10.1016/j.alit.2014.11.002

Source DB:  PubMed          Journal:  Allergol Int        ISSN: 1323-8930            Impact factor:   5.836


  6 in total

1.  Leukotriene E4 elicits respiratory epithelial cell mucin release through the G-protein-coupled receptor, GPR99.

Authors:  Lora G Bankova; Juying Lai; Eri Yoshimoto; Joshua A Boyce; K Frank Austen; Yoshihide Kanaoka; Nora A Barrett
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-16       Impact factor: 11.205

Review 2.  Lipid Mediators of Allergic Disease: Pathways, Treatments, and Emerging Therapeutic Targets.

Authors:  Eric Schauberger; Miriam Peinhaupt; Tareian Cazares; Andrew W Lindsley
Journal:  Curr Allergy Asthma Rep       Date:  2016-07       Impact factor: 4.806

3.  Therapeutic potential of an orally effective small molecule inhibitor of plasminogen activator inhibitor for asthma.

Authors:  Rui-Ming Liu; Stephanie Eldridge; Nobuo Watanabe; Jessy Deshane; Hui-Chien Kuo; Chunsun Jiang; Yong Wang; Gang Liu; Lisa Schwiebert; Toshio Miyata; Victor J Thannickal
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-12-23       Impact factor: 5.464

Review 4.  Purinergic Signaling in Mast Cell Degranulation and Asthma.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Front Pharmacol       Date:  2017-12-22       Impact factor: 5.810

5.  Dpep2 Emerging as a Modulator of Macrophage Inflammation Confers Protection Against CVB3-Induced Viral Myocarditis.

Authors:  Xiaoli Yang; Yan Yue; Sidong Xiong
Journal:  Front Cell Infect Microbiol       Date:  2019-03-07       Impact factor: 5.293

Review 6.  Leukotriene Signaling as a Target in α-Synucleinopathies.

Authors:  Katharina Strempfl; Michael S Unger; Stefanie Flunkert; Andrea Trost; Herbert A Reitsamer; Birgit Hutter-Paier; Ludwig Aigner
Journal:  Biomolecules       Date:  2022-02-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.